Brand Name generic name Medication Use Evaluation Pharmacy amp Therapeutics Committee Presenters Name Presentation date Insert Your Organizations Logo Here Background FDA approval date and indication ID: 919683
Download Presentation The PPT/PDF document "Brand Name® (generic name)" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Brand Name® (generic name)
Brand Name® (generic name)
Medication Use EvaluationPharmacy & Therapeutics Committee
Presenter’s Name
Presentation date
Insert Your Organization’s Logo Here
Slide2Background
FDA approval date and indication
Formulary addition dateP&T decision on indication and restrictions [service, indications, patient populations, etc.]
Potential shift from other agents (if applicable)Drug-specific informationRecommended clinical guidelines; REMS statusPurpose of MUE Follow up to 6-, 12- or other- month post-formulary addition review, P&T concerns at time of approval (safety concerns, restriction changes, request for review, etc.)
Follow up on any outcomes recommended as part of the MUE
Slide3Methods
Date range for MUE
Data source [Apex administration data, ordering data, etc]Sampling, if appropriate [e.g., one of every 5 patients who received infusions of drug “x” were included]
Data review: chart review, progress notes, infusion notes, etc.
Slide4Results (limit to 1-3 slides if possible)
Utilization over time period vs estimated use at the time of P&T approval (# of patients, # of doses)
Major findings [e.g., adherence to guidelines, restrictions, appropriate dosing]
Present results as n and % of patients that met criteriaOutcome measures (mortality, therapeutic effectiveness, patient experience, or readmissions. Safety may be included if serious adverse events affect other outcomes of care)Results of discussion with clinical service
Slide5Drug Purchasing Cost
Assumptions from original P&T approval:
Inpatient or outpatient use?
Usual dose/durationEstimated 70 kg
pt (for wt based dosing)MedicationDose/Frequency/durationCost/vial (or other unit)Daily Cost per patientCost per patient per course of therapyBrand Name(generic)__ grams Q__ x ___ daysGPO: 340B: WAC:GPO: 340B:
WAC:
GPO:
340B:
WAC:
Medication
Dose/Frequency/duration
Cost/vial
(or
other unit)
Daily Cost per patient
Cost per patient per course of therapy
Comparator Med
Brand Name
(generic)__ grams Q__ x ___ daysGPO: 340B: WAC:GPO: 340B: WAC:GPO: 340B: WAC:
Please round all costs to
nearest dollar and justify cost to the right so it is easier to read
Slide6Purchasing Cost and Use - Yearly
Estimated
c
ost per patient per course of therapy
Estimatedannual cost (n=___)Actual cost per course of therapyActualannual cost (n=___)MedicationGPO: 340B: WAC:GPO: 340B: WAC:GPO: 340B: WAC:GPO: 340B: WAC:Comparator MedicationGPO: 340B: WAC:GPO: 340B: WAC:
GPO:
340B:
WAC:
GPO:
340B:
WAC:
10/26/2020
Presentation Title and/or Sub Brand Name Here
6
Difference between estimated and actual annual cost and patient numbers:
Please round all costs to
nearest dollar and justify cost to the right so it is easier to read
Slide7Recommendations
Recommended status on formulary
Maintain on formulary, restriction changes, etc.Recommended changes to prescribing/dispensing workflow
Plans for re-assessment or follow-up MUE, if appropriateOutcome plan to carry out in follow up